Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00949780
Other study ID # PUCSP-HC
Secondary ID
Status Completed
Phase Phase 2
First received July 28, 2009
Last updated July 30, 2009
Start date October 2007
Est. completion date October 2008

Study information

Verified date July 2009
Source Pontificia Universidade Catolica de Sao Paulo
Contact n/a
Is FDA regulated No
Health authority Brazil: National Committee of Ethics in Research
Study type Interventional

Clinical Trial Summary

Chloral Hydrate (CH) is a well known drug for sedative and hypnotic purposes used in pediatric and dental procedures owing to the low depressive effect it has over respiratory and cardiac systems. Despite that, the literature reports cases of heart arrhythmia and sudden death in children, especially when using high doses, probably due to accumulation of serum trichloroethanol, an intermediate metabolite resulting from the liver metabolism of the drug. A possible carcinogenic action observed in guinea pigs has also been reported, even though it has not been confirmed in human beings.

Among the least severe complications there are paradoxical agitation, nausea, vomiting and excessive sleepiness.

CH is the drug of choice to sedate children undergoing Auditory Brainstem Response test (ABR), in which any movement or muscle contraction may generate artifacts that interfere in the analysis.

Profound sleep that lasts on average one hour is rapidly induced depending on the used dose, causing no residual sleepiness after this period; however, there is consensus in the literature about the best dose, which may range from 40 to 100 mg/kg.

Objective:

To assess the efficacy of CH as a sedative agent in performing ABR in children and to systematize its use.


Recruitment information / eligibility

Status Completed
Enrollment 41
Est. completion date October 2008
Est. primary completion date March 2008
Accepts healthy volunteers No
Gender Both
Age group 1 Year to 11 Years
Eligibility Inclusion Criteria:

- no success in previous attempts to perform the test during natural sleep

Exclusion Criteria:

- severe heart or lung disease

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Drug:
Chloral Hydrate


Locations

Country Name City State
Brazil Derdic-Pucsp São Paulo
Brazil Mariana Lopes Favero São Paulo

Sponsors (1)

Lead Sponsor Collaborator
Pontificia Universidade Catolica de Sao Paulo

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary 36 patients slept one hour Yes